- Home
- ARBB vs CMMB Comparison
ARBB vs CMMB Comparison
Compare ARBB & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARBB
- CMMB
- Stock Information
- Founded
- ARBB 1997
- CMMB 2004
- Country
- ARBB Singapore
- CMMB Israel
- Employees
- ARBB N/A
- CMMB N/A
- Industry
- ARBB EDP Services
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- ARBB Technology
- CMMB Health Care
- Exchange
- ARBB Nasdaq
- CMMB Nasdaq
- Market Cap
- ARBB 13.3M
- CMMB 13.7M
- IPO Year
- ARBB 2023
- CMMB N/A
- Fundamental
- Price
- ARBB $5.36
- CMMB $3.10
- Analyst Decision
- ARBB Strong Buy
- CMMB Strong Buy
- Analyst Count
- ARBB 1
- CMMB 2
- Target Price
- ARBB $20.00
- CMMB $26.50
- AVG Volume (30 Days)
- ARBB 59.8K
- CMMB 268.6K
- Earning Date
- ARBB 11-26-2025
- CMMB 11-13-2025
- Dividend Yield
- ARBB N/A
- CMMB N/A
- EPS Growth
- ARBB N/A
- CMMB N/A
- EPS
- ARBB N/A
- CMMB N/A
- Revenue
- ARBB $24,425,491.00
- CMMB N/A
- Revenue This Year
- ARBB N/A
- CMMB N/A
- Revenue Next Year
- ARBB $462.92
- CMMB N/A
- P/E Ratio
- ARBB N/A
- CMMB N/A
- Revenue Growth
- ARBB N/A
- CMMB N/A
- 52 Week Low
- ARBB $3.92
- CMMB $2.39
- 52 Week High
- ARBB $18.60
- CMMB $9.84
- Technical
- Relative Strength Index (RSI)
- ARBB 39.77
- CMMB 52.91
- Support Level
- ARBB $5.00
- CMMB $3.11
- Resistance Level
- ARBB $6.96
- CMMB $3.50
- Average True Range (ATR)
- ARBB 0.64
- CMMB 0.25
- MACD
- ARBB -0.29
- CMMB -0.02
- Stochastic Oscillator
- ARBB 9.23
- CMMB 48.86
About ARBB ARB IOT Group Limited
ARB IOT Group Ltd is engaged in provision of hardware and software of Internet of Things Solutions to meet customers' demand in four business lines, which are IoT Smart Home and Buildings, IoT Smart Agriculture, IoT System Development, and IoT Gadget Distribution. The company delivers holistic solutions with full turnkey deployment from designing, installation, testing, pre-commissioning, and commissioning of various IoT systems and devices as well as integration of automated systems, including installation of wire and wireless and mechatronic works. The company has two operating segments: Internet of Things ('IoT'), Investment holding and others. It earns its maximum profit from the Internet of Things (IoT) segment.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.